We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
Read MoreHide Full Article
Mylan N.V. announced that it has inked an agreement with Israel-based Mapi Pharma Ltd.
Both companies have teamed up for the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan also acquired the global marketing rights of the product.
We note that GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (“MS”), or RRMS. Mapi Pharma has completed an open-label phase II trial. The company is also preparing to commence phase III trials to support marketing applications. Both companies are preparing to submit an investigational new drug application to the FDA, as well as other global health authorities.
We remind investors that Mylan already has experience in the Glatiramer Acetate market.
In October 2017, Mylan launched the generic version of Teva's (TEVA - Free Report) Copaxone 40 mg/mL which is indicated for the treatment of patients with relapsing forms of MS. Mylan’s partner in Europe, Synthon, also received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL.
An estimated 2.3 million people on a worldwide basis are living with MS. Nearly 1 million people are living with MS in the United States. RRMS accounts for approximately 85% of initial MS diagnoses.
The deal with Mapi Pharma will further strengthen the company’s presence in the MS market.
Mylan’s stock has gained 9.9% in the last six months, as against the industry’s decline of 10.1%.
Mylan has one of the largest product portfolios among all generic pharmaceutical companies. With the acquisition of the Topicals Business, Mylan gained a complementary portfolio of approximately 25 branded and generic topical products, including an active pipeline of approximately 25 products as well as established United States sales and marketing infrastructure targeting dermatologists. The Topicals Business added to Mylan an integrated manufacturing and development platform along with a leading topicals-focused contract development and manufacturing organization.
Mylan is also exploring the world of biosimilars. The company formed a partnership with Biocon and also has a collaboration agreement with Momenta Pharmaceuticals . The company also received an FDA approval for a biosimilar version of Roche Holdings’ (RHHBY - Free Report) Herceptin.
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
Mylan N.V. announced that it has inked an agreement with Israel-based Mapi Pharma Ltd.
Both companies have teamed up for the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan also acquired the global marketing rights of the product.
We note that GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (“MS”), or RRMS. Mapi Pharma has completed an open-label phase II trial. The company is also preparing to commence phase III trials to support marketing applications. Both companies are preparing to submit an investigational new drug application to the FDA, as well as other global health authorities.
We remind investors that Mylan already has experience in the Glatiramer Acetate market.
In October 2017, Mylan launched the generic version of Teva's (TEVA - Free Report) Copaxone 40 mg/mL which is indicated for the treatment of patients with relapsing forms of MS. Mylan’s partner in Europe, Synthon, also received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL.
An estimated 2.3 million people on a worldwide basis are living with MS. Nearly 1 million people are living with MS in the United States. RRMS accounts for approximately 85% of initial MS diagnoses.
The deal with Mapi Pharma will further strengthen the company’s presence in the MS market.
Mylan’s stock has gained 9.9% in the last six months, as against the industry’s decline of 10.1%.
Mylan has one of the largest product portfolios among all generic pharmaceutical companies. With the acquisition of the Topicals Business, Mylan gained a complementary portfolio of approximately 25 branded and generic topical products, including an active pipeline of approximately 25 products as well as established United States sales and marketing infrastructure targeting dermatologists. The Topicals Business added to Mylan an integrated manufacturing and development platform along with a leading topicals-focused contract development and manufacturing organization.
Mylan is also exploring the world of biosimilars. The company formed a partnership with Biocon and also has a collaboration agreement with Momenta Pharmaceuticals . The company also received an FDA approval for a biosimilar version of Roche Holdings’ (RHHBY - Free Report) Herceptin.
Zacks Rank
Mylan carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here..
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>